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Magic Bullets for Mental Disorders: The Emergence
of the Concept of an “Antipsychotic” Drug
JOANNA MONCRIEFF
Department of Mental Health Sciences, University College London, London, UK
When “antipsychotic” drugs were introduced into psychiatry in the 1950s, they were
thought to work by inducing a state of neurological suppression, which reduced behav-
ioral disturbance as well as psychotic symptoms. This view was reflected in the name
“neuroleptic.” Within a few years, however, the idea that the drugs were a disease-spe-
cific treatment for schizophrenia or psychosis, and that they worked by modifying the
underlying pathology of the condition, replaced this earlier view, and they became
known as “antipsychotics.” This transformation of views about the drugs’ mode of
action occurred with little debate or empirical evaluation in the psychiatric literature
and obscured earlier evidence about the nature of these drugs. Drug advertisements
in the British Journal of Psychiatry reflect the same changes, although the nondis-
ease-specific view persisted for longer. It is suggested that professional interests rather
than scientific merit facilitated the rise of the disease-specific view of drug action.
The increasing popularity of atypical antipsychotics makes it important to examine the
origins of the assumptions on which modern drug treatment is based.
Keywords antipsychotics, history of psychopharmacology, psychiatric therapeutics,
treatment specificity
The inscription on the Lasker prize awarded in 1957 read, “for the introduction of
chlorpromazine into psychiatry and for the demonstration that a medication can influence
the clinical course of the major psychoses” (Deniker, 1989, p. 253). These words encap-
sulate the importance that was attributed to finding a physical intervention for psychiatric
disorders that was more than just a sticking plaster and to finding something that could
change the very nature of the disorder itself. Although chlorpromazine and other early
antipsychotics were thought to be uniquely useful in the treatment of psychiatric conditions,
few people believed at this time, however, that the drugs acted on the disease process itself.
The idea that they acted in a disease-specific or “disease-centered” manner developed later,
but as the inscription suggests, psychiatry was already aspiring towards such a treatment.
With the discovery of anti-infective agents like Salvarsan and the sulphonamides,
and the isolation and synthesis of the hormones insulin and thyroxine, medicine in the
twentieth century became strongly associated with the notion that medical treatment
could target the underlying disease. “Cure by specific therapy” became “the only really
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Magic Bullets for Mental Disorders 31
proper sphere for the physician” (Pellegrino, 1979, p. 255). This new orientation, which
replaced the humoral model of disease, placed greater power in the hands of the physician.
A specialized knowledge of the mechanics of the body and how it could go wrong, which
was not available to the layman, was required to identify a particular disease and its
corresponding cure or treatment. The greater efficacy of specific treatments justified the
greater power and prestige accorded to the medical profession (Rosenberg, 1986) and
medicine has continued to deliver drugs that target the physiological processes underlying
particular diseases or symptoms.
Although there is much debate about the inclinations of psychiatry in the mid-twentieth
century, and whether and to what extent it was dominated by psycho-analytical or biolog-
ical theories of mental disorder, most commentators agree that, from the 1950s, there was
an emphasis on biological theories and treatments (Shorter, 1997; Healy, 2002). One of
the major developments in psychiatry at this time was the introduction of a new range
of psychopharmaceuticals, starting with chlorpromazine and followed by a number of
other drugs, that came eventually to be known as “antipsychotics.” Although various
types of sedative drugs had been used prolifically in psychiatry prior to the introduction
of chlorpromazine, they were not regarded as worthy of attention and were viewed as
acting essentially as chemical restraints (Braslow, 1997; Moncrieff, 1999b). In contrast,
chlorpromazine and other drugs introduced subsequently appeared to follow in the foot-
steps of physical treatments like insulin coma therapy and electroconvulsive therapy (ECT),
which had been introduced to great acclaim from the 1930s and which inspired the view
that an intervention applied to the body could alter the course of a mental condition, rather
than simply containing disturbed behavior (Moncrieff, 1999b).
The new drugs were not at first, however, credited with disease-specific effects. Early
publications suggest they were understood as producing a particular drug-induced state, a
special sort of sedation, that was useful in situations involving agitation, confusion, distur-
bance, or psychosis (Moncrieff, 2008b; Whitaker, 2002). Elsewhere, I have referred to this
view as the “drug-centered” model of psychiatric drug action to emphasize how psychiatric
drugs are psychoactive substances like alcohol and opiates and that modify normal feel-
ings and behavior, producing an altered state of consciousness. According to this model,
the altered, drug-induced state is understood to suppress or mask the symptoms of mental
distress or disturbance (Moncrieff & Cohen, 2005).
In contrast, current discussions of psychiatric drugs, including antipsychotics, are
based on the assumption that they act in a disease-specific or “disease-centered” manner
(Moncrieff & Cohen, 2005; Moncrieff, 2008b). According to this view, psychiatric drugs
are effective because they reverse or modify the physiological processes that are hypoth-
esized to produce particular mental symptoms in the same way that drugs work in other
areas of medicine.1 According to this view, the altered state or psychoactive effects that
drugs produce are merely incidental “side effects” and irrelevant to their therapeutic actions.
Although assumptions about the mechanism of action of drug treatment in psychiatric liter-
ature remain largely implicit, current textbooks provide detailed coverage of the effects of
drugs on various neurotransmitter systems and of theories of underlying neurotransmitter
abnormalities in psychiatric disorders, such as the dopamine hypothesis of schizophrenia,
but omit any serious discussion of the psychoactive effects of drugs (the way they modify
1The vast majority of medical drugs target the underlying mechanisms that produce symptoms
or disorders. Anti-asthma drugs, for example, work by dilating constricted airways, anticancer drugs
by targeting mechanisms of cell proliferation, and pain killers act on the physiological pathways that
produce pain.
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32 Joanna Moncrieff
normal feelings and behavior) and their impact on mental symptoms (see, for example, The
New Oxford Textbook of Psychiatry; Meltzer & Babo, 2009). The latest edition of the princi-
ple American textbook of psychiatry, although suggesting that classifying drugs according
to “their major indications is problematic” (Sussman, 2009, p. 2967), stresses that “mental
disorders are true medical conditions that can benefit from drug therapy in the same way
that diabetes, asthma and hypothyroidism, and other chronic disorders are responsive to
medication” (Sussman, 2009, p. 2985).
Literature produced for public consumption sometimes makes more explicit claims.
A leaflet on schizophrenia produced by the American Psychiatric Association in 1996 sug-
gested that antipsychotic drugs “help bring biochemical imbalances closer to normal”
(American Psychiatric Association, 1996, p. 7) and leaflets on antidepressants make simi-
lar claims (Royal College of Psychiatrists, 2007). Information produced by drug companies
also stresses the rectification of underlying chemical imbalances as the mechanism of action
of antipsychotics and other drugs. Eli Lilly, for example, describes how “antipsychotic
medicines are believed to work by balancing the chemicals found naturally in the brain”
(Eli Lilly, 2011).
The emergence of the disease-specific view in the 1950s and 1960s has been noted
by several authors (Healy, 2002; Whitaker, 2002; Gelman, 1999). In the current article, I
present a detailed exploration of the evolution of ideas about the mechanism of action of the
new “antipsychotic” drugs between the 1950s and the 1970s. To examine the psychiatric
perspective, I analyzed psychiatric papers, textbooks, conference proceedings, and remi-
niscences of eminent psychopharmacologists, including the three volumes of interviews
conducted by David Healy (1996, 1999, 2000). I also examined advertisements published
in the Journal of Mental Science (later named the British Journal of Psychiatry) yearly
between 1955 and 1960 and then every five years up to 1980 to ascertain how antipsychotics
were presented as working in promotional material. Due to their relative independence from
the prevailing academic consensus, advertisements, as well as reflecting commercial con-
cerns, may provide useful clues as to how drugs were used and perceived in everyday
practice. Using these sources I describe early ideas about the actions of the new drugs and
the development of the view that they exerted disease-specific effects in certain conditions,
particularly schizophrenia or the broader category of psychosis. I also contrast the emerg-
ing academic and professional consensus on disease-specificity with the more varied and
opportunistic stance of the pharmaceutical industry.
Early Accounts of the New Drugs
Judith Swazey’s detailed account of the development of chlorpromazine and its intro-
duction into psychiatry illustrates how early reports provided detailed descriptions of the
characteristic mental and physical effects induced by the drug (Swazey, 1974). These
descriptions consistently emphasize the emotional indifference produced by the drug or the
related idea of a reduction in responsiveness to external events. Laborit, the naval surgeon
who used the drug in his anesthetic “cocktail,” describes the “twilight state” induced by the
drugs (Laborit & Huguenard, 1951), which he notes later is characterized by a “disinterest-
edness” in external events (Laborit, Huguenard, & Alluaume, 1952). French psychiatrists
Jean Delay and Pierre Deniker, who heard about Laborit’s use of chlorpromazine and
started using it in their psychiatric patients, described its “psychic effects” (Delay, Deniker,
& Harl, 1952, p. 115) in a series of conference presentations, later published as papers in
1952. In their report of the treatment of 38 patients with “excited states,” they described the
drug-induced state in some detail, concluding that
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Magic Bullets for Mental Disorders 33
The apparent indifference, or delay in response to external stimuli, the emo-
tional and affective neutrality, the decrease in both initiative and preoccupation
without alteration of conscious awareness or in intellectual faculties constitute
the psychic syndrome due to treatment. (Delay & Deniker, 1952, pp. 503–504)
Other psychiatrists who reported on the use of chlorpromazine in these early days made
similar observations. Parisian neurologists, Sigwald and Bouttier, who gave the drug to
their neurological outpatients, noted how it reduced the distress associated with delu-
sions and hallucinations and lessened the “imperative character” of obsessional thoughts
(Sigwald & Bouttier, 1953, p. 176). British psychiatrist Anton-Stephens described its main
effects as “somnolence” and “psychic indifference,” which he deemed to be most useful in
“quieting disturbed behaviour” (Anton-Stephens, 1954, p. 557). In their report of the first
clinical trial of chlorpromazine, Joel and Charmian Elkes of Birmingham commented on
how patients on chlorpromazine became “quieter and more amenable to suggestion by the
nursing staff” and, although their psychotic symptoms persisted, they were “less disturbed”
by them (Elkes & Elkes, 1954, p. 563). Heinz Lehmann, who introduced chlorpromazine
to Canada, noted that the drug made patients lethargic and that “patients under treatment
display a lack of spontaneous interest in their environment, yet are easily accessible and
respond as a rule immediately and relevantly to questions, even if awakened from sleep”
(Lehmann & Hanrahan, 1954, p. 230).
In 1954, two separate researchers, Professor Hans Steck of Lausanne and German
psychiatrist Hans Joachim Haase, provided the first unambiguous descriptions of
chlorpromazine’s effects on the neurological motor system, now generally referred
to as extra-pyramidal side effects. They both remarked on the similarity between the
drug-induced effects: the decreased movement, reduced facial expression, loss of initiative
and muscular rigidity, and the symptoms of Parkinson’s disease. They also described the
drug-induced agitation known as akathisia (Steck, 1954; Haase, 1954). Within a couple of
years, these neurological effects were well recognized, and other neurological effects had
been identified including muscular spasms and involuntary movements (Hollister, 1957;
Kline, 1956).
The Concept of a Neuroleptic
In early attempts to define the nature of drugs like chlorpromazine and reserpine, Delay
and Deniker stressed two aspects of the drugs’ effects: the peculiar nature of the sedation,
which, in contrast to barbiturates, produced a sleep from which people could be easily
roused, and the state of disinterest produced by the drugs (Deniker, 1956; Delay & Deniker,
1956). They saw the motor effects as incidental rather than primary, but the sedation and
indifference were also regarded as neurological effects by virtue of being induced by
drug action on the brain and nervous system. In early papers, therefore, they referred to
chlorpromazine as a “neuroplegic” drug (from the Greek to paralyze),2 and, in 1955, they
replaced this term by the term “neuroleptic” (from the Greek to seize), still emphasizing
the sedative and emotional effects of the drug, rather than its motor effects (Delay &
Deniker, 1955).
2The term “neuroplegic” reflects the influence of Laborit’s search for what he called “ganglio-
plegic” drugs, which were drugs used to paralyze or suppress the ganglia or nervous system (Healy,
2002; Swazey, 1974).
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 05
:55
 28
 Ju
ly 
20
14
 
34 Joanna Moncrieff
In 1957, Delay and Deniker came across a new drug called prochlorperazine, which
was being tested in psychiatric patients by Pierre Brousolle and others working in Lyon.
Prochlorperazine was a phenothiazine like chlorpromazine but was much less sedating
in its actions and produced dramatic neurological reactions, described at the time as
“excito-motor” effects, including muscular spasms, severe akathisia, and other movement
abnormalities both in psychiatric patients, and in military personnel who were given the
drug against sea sickness (Delay, Deniker, Green, & Mordret, 1957; Comite Lyonnais de
Recherches Therapeutiques en Psychiatrie, 2000). Deniker later recalled that the experience
of using prochlorperazine persuaded him and Delay that characteristic abnormal motor
effects were an intrinsic part of the neurological state produced by the drugs (Deniker,
1989).
Deniker outlined the theory behind the idea of a neuroleptic most explicitly in a paper
published in 1960, entitled “Experimental Neurological Syndromes and the New Drug
Therapies in Psychiatry” (Deniker, 1960). In this paper, he suggested that the neuroleptics
act through inducing a neurological syndrome, somewhat similar to the postencephalitis
type of Parkinson’s disease. As in his other publications, he described in some detail the
way the drug made patients look and behave. Thus, he noted how patients “look as if they
have been turned to stone, they are usually indifferent to themselves and their environment,
they are stuporous or prostrate, even before the clinical symptom of hypertonia (rigidity)
appears” (Deniker, 1960, p. 96). Although Deniker admitted that he had previously found
chlorpromazine useful in doses low enough not to cause obvious physical symptoms, in this
paper, he asserted the notion that it was necessary to “resolutely and systematically aim to
produce neurological syndromes to get better results than can be obtained when neuroleptic
drugs are given at less effective doses” (Deniker, 1960, p. 100).
German psychiatrist, Hans-Joachim Haase also proposed that the therapeutic effects
of the new drugs consisted of a mild version of the Parkinson disease-like syndrome they
induced (Haase, 1956). Later, he coined the term “neuroleptic threshold” to indicate the
dose of a drug that could achieve therapeutically useful, mild neurological suppression,
without producing frank Parkinsonian symptoms (Haase & Janssen, 1965).
Similar views were proposed by American psychiatrist, F. A. Freyhan, speaking at a
symposium held in Switzerland in 1957 (Freyhan, 1959). He stressed the belief that the
effects of the new drugs were not specific to any diagnostic group but acted on signs of
overarousal, excitement, and abnormal preoccupations due to their ability to reduce move-
ment and initiative and blunt emotions. Like Deniker and Haase, Freyhan suggested that the
drugs useful or therapeutic effects were on a continuum with their obvious extra-pyramidal
or Parkinsonian effects:
From the beginning it was evident that no lines of demarcation could be
drawn between therapeutic degrees of reduced psychomotor activity and early
symptoms of parkinsonism. . . . What we witnessed were gradual transition
from hypermotility to hypomotility, which, in a certain proportion of patients,
progressed to the more pronounced degrees of parkinsonian rigidity. Clinical
evidence therefore, indicated that the therapeutic function of chlorpromazine
and reserpine could not be separated from their modifying influence on the
function of the subcortical motor system in transacting volitional, affective and
intentional functions. (Freyhan, 1959, p. 10)
Psychiatrists in England and Canada echoed these views (Denham, 1965; Sarwer-Foner,
1960), and there was also support for the view that inducing the neurological symptoms
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Magic Bullets for Mental Disorders 35
of Parkinsonism was necessary to achieve the therapeutic benefits of the neuroleptics
(Denham & Carrick, 1960; Karn & Kasper, 1959; Flugel, 1959). The “drug-centered” view-
point was summarized by participants at a symposium held in 1955, who concluded that
chlorpromazine could be used to “attain a neuropharmacologic effect, not to ‘cure’ a dis-
ease” (Smith Kline & French Laboratories, 1955, p. 158 as cited in Whitaker, 2002, p. 146).
From Tranquilizers to Antipsychotics
The idea of a neuroleptic was never accepted to the same degree in America. There,
drugs like chlorpromazine and reserpine were referred to as “tranquilizers,” and later as
“major tranquilizers,” to distinguish them from meprobamate, and the newly launched
benzodiazepine, Librium, which were increasingly labelled as “minor tranquilisers.”3
As early as 1954, participants at a psychiatric symposium in Washington, DC, clearly
stated that they believed chlorpromazine and reserpine were attacking the “underlying
schizophrenic process” (Kinross-Wright, 1956) and exerting a “specific effect on the basic
schizophrenic mechanisms” (Sainz, 1956). A participant, who did not share this view,
bemoaned the tendency to jump from the effects of drugs to making generalizations about
the genesis of psychotic behavior (Meyers, 1956). In 1955, the President of the Society of
Biological Psychiatry of the United States reflected that the new drugs were of a “differ-
ent order” from previous drugs, and that they could “wipe out the symptoms of psychotic
patients just as internists can use insulin for the elimination of the symptoms of diabetes”
(Himwich, 1955, p. 421).
At the same symposium in 1957 in which Freyhan outlined his drug-centered view
of the action of the new tranquilizers, Heinz Lehman set out the first explicit, although
brief, disease-centered view of the actions of chlorpromazine and similar drugs (Lehmann,
1959). As well as attempting to classify the new drugs by their physiological effects on
the nervous system, in other words, whether they exerted “inhibiting,” “exciting,” or psy-
chotomimetic effects, he suggested that the effects of drugs could be divided into those
that were “curative,” “corrective,” and “symptomatic.” Whereas, a curative substance was
one that reversed the original cause of the disease, like antibiotics, a corrective was one
that attacked a “nucleus of symptoms that is fairly close to the primary disturbance,”
although the primary cause of the condition need not be known. Examples of correctives in
medicine were insulin for diabetes and digitalis for heart disease, and Lehmann identified
chlorpromazine and reserpine as “typical corrective agents in a number of acute and chronic
psychotic conditions” (1959, p. 22). He contrasted their effects to symptomatic treatments,
like morphine for pain, barbiturates for insomnia, and chlorpromazine when it was used
for the control of behavioral excitement, which only affected symptoms that were “rather
remote and indirect manifestations” of the disease process (Lehmann, 1959, p. 23).
Heinz Lehmann has said that he introduced the term “antipsychotic” at a Canadian
Medical Association meeting in 1956, but that he meant it more metaphorically than liter-
ally at this time (Lehmann, 1993). The first paper listed on Medline to use the term was
published in 1962,4 in which two psychiatrists distinguished an “antipsychotic drug” that
“antagonises major psychotic symptoms” from other tranquilizers, which ameliorate the
“symptom of anxiety” (Mapp & Nodine, 1962, p. 458). Despite this distinction, however,
3The first use of the term “tranquiliser” (or “tranquilizer”) on Medline is in reference to meproba-
mate in a paper published in March 1956. It was first used to refer to reserpine later the same year
(June 1956). The term “major tranquilizer” first appears on Medline in a paper from 1960.
4Medline was searched from 1955 to 1970 for papers using the exact term “antipsychotic.”
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36 Joanna Moncrieff
they did not attribute “curative” or “corrective” properties (in Lehmann’s terms) to the
drugs they were describing but expressed confidence that “more specific agents” would be
discovered in the future that would act on the “etiology of the symptoms rather than the
symptoms themselves” (Mapp & Nodine, 1962, p. 463).
One of the most influential figures to promote the disease-centered theory of drug
action was American psychiatrist Nathan Kline (Healy, 2002). In 1959, he described
chlorpromazine and reserpine as “ataraxics,” meaning, according to Kline, “freeing from
turmoil and confusion” (Kline, 1959, p. 398). He also stated that the really unique property
of the drugs was to “remove, reverse, restrict or inhibit” mental symptoms, including those
of psychosis (Kline, 1959, p. 398). But it was his characterization of what later came to
be known as “antidepressants” that expressed disease-specific ideas most explicitly. Kline
distinguished these drugs from stimulants, which were known to cause physical arousal and
to elevate mood to the point of euphoria. In contrast, he said, drugs that he called “psychic
energizers” (later referred to as antidepressants), which had previously been described as
stimulant-type substances (Crane, 1956), did not cause euphoria but normalized mood in
those who were depressed (Kline, 1959).
In 1964, a well-known study funded by the United States National Institute for
Mental Health (NIMH) claimed to have demonstrated the disease-specific effects of
the new drugs for the treatment of schizophrenia (National Institute of Mental Health
Psychopharmacology Service Center Collaborative Study Group, 1964). The trial, which
involved chlorpromazine and two other recently introduced drugs, found that all three drugs
improved a range of symptoms greater than the placebo. Since these symptoms included
not just excitement, agitation, and anxiety but what were regarded as more fundamental
schizophrenic symptoms including incoherence of speech, social withdrawal, and apathy, as
well as auditory hallucinations and persecutory delusions, the authors concluded that “the
phenothiazines should be considered to be ‘anti-schizophrenic’ in the broad sense. In fact,
it is questionable whether the term ‘tranquiliser’ should be retained” (National Institute
of Mental Health Psychopharmacology Service Center Collaborative Study Group, 1964,
p. 257). They also noted that the drugs tested varied in their proclivity to produce extrapyra-
midal or Parkinsonian effects, and yet, because all were equally effective, they suggested
that “the therapeutic properties of these drugs may be quite independent of their tendency
to produce side effects” (National Institute of Mental Health Psychopharmacology Service
Center Collaborative Study Group, 1964, p. 255).
Sheldon Gelman has described how the report of this trial encapsulated a new psychi-
atric “vision” that suggested that drug treatment was effective and specific with relatively
trivial adverse effects (Gelman, 1999). The trial was not designed to demonstrate how the
drugs worked, however. In particular, there was no comparison with other sedatives, no
consideration of the nature of the altered state produced by the drugs and its impact on
symptoms, and the neurological “extrapyramidal” effects were already conceptually dis-
tinguished from the drugs’ therapeutic effects and were referred to as “side effects.” The
concept of the “neuroleptic threshold,” which suggests that drugs with different propensi-
ties to cause extrapyramidal effects can exert therapeutic neurological effects at variable,
“threshold” doses, was ignored.
The Ascendancy of the Disease-Centered View
The idea that drugs like chlorpromazine could suppress a range of psychotic symp-
toms does not in itself necessarily imply a disease-centered view of drug action. But the
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Magic Bullets for Mental Disorders 37
language used, the separation and minimization of neurological “side effects,” and the
broad endorsement of the drugs suggest that they were in the process of being transformed
into drugs that were comparable to other, specific medical treatments.
This transformation happened with almost no direct discussion or debate. Although a
few figures like Deniker and Haase continued to reiterate a drug-centered view, in general,
what is striking is that this older conception of drug action simply faded away. Descriptions
of the neurological and general effects induced by neuroleptics and other psychiatric drugs,
such as antidepressants, disappeared from the literature (Moncrieff, 2008a) and were hence-
forth referred to, if at all, only as “side effects,” which were regarded as an incidental
nuisance, rather than an intrinsic part of a drug’s action. Almost no papers discussed
the relative merits of different theories of drug action or attempted to justify the disease-
centered model, and no research was set up to evaluate different models. When textbooks
started to present the disease-centered view, there was no acknowledgement that there were
alternative explanations of how antipsychotics might work.
Psychiatric textbooks tentatively started to convey a disease-centered view of the nature
of antipsychotic drugs from the 1960s. The principle British textbook of the period was
edited by two well-known socially inclined psychiatrists. In the 1962 edition, they hes-
itated to call the new tranquilizers “specific” but felt that “they appear to do more than
tranquilise” (Henderson & Gillespie, 1962, p. 350). A more biologically oriented textbook
was bolder, suggesting that the “drugs penetrate much closer to the site of mechanism of
the disease itself than any other procedure applied hitherto” (Mayer-Gross, Slater, & Roth,
1960, p. 386). By 1969, the section on drug treatment of schizophrenia concluded that
“phenothiazine drugs cannot be regarded as being merely symptomatic therapies in the
same sense as analgaesic drugs” (Mayer-Gross, Slater, & Roth, 1969, p. 330).
The Companion to Psychiatric Studies was published for the first time in 1973 and
became one of the most respected British textbook for the next few decades. The gen-
eral chapter on pharmacology in the first edition presented a drug-centered account of
the effects of neuroleptics, suggesting that the drugs damp down responses to stimuli and
reduce spontaneity. Following Delay and Deniker, it described the drugs’ unique quality as
their ability to induce sedation without sleep (Roberts, 1973). The chapter on the treat-
ment of schizophrenia, however, written by a different author, assumed that the drugs
act in a disease-centered manner (Smythies, 1973). The chapter refers to the drugs as
being “anti-schizophrenic” and it is asserted that “there is now abundant evidence from
well-controlled trials that the phenothiazines and butyrophenones exert a specific thera-
peutic effect in schizophrenia, and that the term ‘tranquiliser’ is a misnomer” (Smythies,
1973, pp. 281–282). The author also speculated on the role of dopamine and serotonin
in the drug’s mechanism of action and suggests that if this could be clarified, then the
“biochemical lesion of schizophrenia” (Smythies, 1973, p. 282) would be elucidated.
The largest American textbook of the mid-twentieth century, The American Handbook
of Psychiatry, first published in 1959 and again in 1966, made no explicit comments about
the mode of action of the drugs, although effects were divided into therapeutic effects and
side effects, and there was no description of the altered state the drugs induce and how
this might impact on symptoms (Hoch, 1959; Malitz & Hoch, 1966). In the second edition,
published in 1975, it was claimed that “specific pharmacological treatments for the major
psycho-pathological states have become available” and that these agents were able to elu-
cidate the biochemical origins of these disorders (Maas & Garver, 1975, p. 427). In the
chapter called “Antipsychotic Drugs,” written by Jonathan Cole, the lead researcher on the
NIMH study, and John Davis another well-known academic, it was asserted that the drugs
are “most correctly called ‘antischizophrenic’ or ‘antipsychotic’ drugs. They do not, in any
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real sense, produce a state of tranquillity in either normal or psychotic individuals” (Davis
& Cole, 1975, p. 446). Research on dopamine was described, and it was speculated that the
drugs may exert their effects by reducing dopamine activity.
By 1980, the first edition of what has subsequently become the major American text-
book of psychiatry unequivocally asserted the disease-centered position. The section on
antipsychotic drugs, written by John Davis, stated “antipsychotic drugs have a normalizing
effect. They lessen the typical schizophrenic symptoms, such as hallucinations and delu-
sions. They also normalize various other abnormal behaviors” (Davis, 1980, p. 2260). Davis
also stressed that “there is a clear cut difference between their sedative and antipsychotic
properties” and, in contrast to earlier views, suggested “it is a mistake to think of those
drugs as a special type of sedative” (Davis, 1980, p. 2260). Solomon Snyder, author of
the general section on psychopharmacology, asserted that the drugs “exert a selective
anti-schizophrenia action,” following with a detailed description of their actions on the
dopamine system (Snyder, 1980, p. 161).
None of the textbook sections provide any citations or evidence to support the disease-
centered view of drug action, although many are reminiscent of points made in the NIMH
study report (National Institute of Mental Health Psychopharmacology Service Center
Collaborative Study Group, 1964).
A rare discussion of alternative understandings of drug action by Nathan Kline in
1969 reveals how much was felt to be at stake by acknowledging the drug-centered point
of view. In his 1959 paper, Kline rejected the concept of a neuroleptic, with the reasoned
justification that the mode of action the term suggested was unproven. Ten years later, he
dismissed a World Health Organization report on psychopharmacology that had accepted
the concept, presumably under Deniker’s influence, with invective and bluster. He described
the report as being “deGaulling” in its “capitulation” to the French point of view, and as
using a “weasling excuse” to defend its position (Kline, 1969). Although characteristic of
Kline’s forthright personality (Healy, 2002), the language and tone of his comments, far
removed from the usual academic form of expression, indicate how challenging the notion
of the neuroleptic was by then felt to be, and how strongly Kline wanted to bury it.
The Portrayal of the New Drugs in Advertisements
Although advertisements in the British Journal of Psychiatry also illustrate the transforma-
tion of views about the nature of the new drugs and their mechanism of action, the desire
to appeal to a large market meant that some substances continued to be marketed for their
sedative actions in a range of conditions or situations, well into the 1970s.
The first advertisement for a drug that would now be considered an antipsychotic was
published in 1956 and concerned reserpine. It described reserpine in clearly drug-centered
terms as having “remarkable calming and relaxing action . . . capable of wide application
in mental illness” (Reserpine advertisement, 1956). In 1960, a four-page color advertise-
ment for Melleril, featuring a large picture of a calm and beautiful lake, also stressed the
“psychosedative” action of the drug, describing it as “the tranquiliser pure and simple”
(Melleril advertisement, 1960). All the “antipsychotic” drugs featured in the 1960 editions
of the journal, with the exception of Stelazine (trifluoperazine), which was only advertised
for use in schizophrenia, were recommended for a broad spectrum of psychiatric condi-
tions, including anxiety, agitation in the elderly, and childhood behavior problems, as well
as the treatment of schizophrenia.
By 1965, hints of a disease-centered view appeared, with the use of terms like
“psychocorrective” (Largactil or chlorpormazine; Largactil advertisement, 1965) and
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“profound” (Serenace or haloperidol; Serenace advertisement, 1965) to describe the action
of the drugs in the management of schizophrenia. One advertisement for Stelazine, which
was first printed in February picturing a troubled-looking elderly man, with the caption
“withdrawal” (Stelazine advertisement, 1965a), by August had added a second picture of a
younger man, looking comfortable and relaxed and lying on a couch reading a book. The
clear implication was that Stelazine restores normality (Stelazine advertisement, 1965b).
Most of the drugs, however, were still aimed at a broad range of situations and there were
still references to drug-induced effects such as calming, control, and sedation (Melleril
advertisement, 1965).
In 1970, Neulactil (pericyazine) was being recommended for “behaviour disorders at
all ages” (Neulactil advertisement, 1970), but advertisements for Triperidol (trifluperidol;
Triperidol advertisement, 1970), Serenace (Serenace advertisement, 1970), and Melleril
were specifically aimed at schizophrenia (there were no adverts for Stelazine in this year).
The Melleril advertisement, which consisted of two color pages, claimed that Melleril
“strikes promptly at the target symptoms” and referred to the drug as an “anti-psychotic.”
The effect on target symptoms, which was said to occur after seven days, was also dis-
tinguished from the immediate sedative or “tranquilizing effect” of the drug (Melleril
advertisement, 1970).
In 1975, Fentazin (perphenazine; Fentazin advertisement, 1975) and Serenace
(Serenace advertisement, 1975) were still being recommended in a variety of situations, but
most advertisements concerned long-acting, injectable depot medications that were aimed
exclusively at people with schizophrenia or psychotic disorders. None of the advertise-
ments mentioned any psychoactive properties of the drugs. In June 1975, a new drug called
Redeptin was advertised for the first time, with explicit claims of a disease-centered action.
It was said to have a “specific action on dopamine receptors” (see below) and was referred
to as having an “antipsychotic” action (Redeptin advertisement, 1975).
By 1980, only the newly launched Droleptan (droperidol), which was still described
as a “major tranquilizer,” was being advertised for nonspecific purposes: the “rapid control
of acute agitation” (Droleptan advertisement, 1980). A large number of advertisements for
other antipsychotic agents were aimed specifically at the treatment of schizophrenia, but
none provided any explanation of the mechanism of action of the drugs in any terms.
The Dopamine Hypothesis of Schizophrenia
The dopamine hypothesis of schizophrenia is clearly important to the current discus-
sion, although a detailed history of the hypothesis would constitute another article in
its own right. The origins of the dopamine theory of schizophrenia are often dated to a
paper published in 1963 by the renowned Swedish pharmacologist Arvid Carlsson. In this
paper, he showed that haloperidol and chlorpromazine affected the synthesis of catechol
amines, including dopamine (Carlsson & Lindqvist, 1963). In 1966, a Dutch researcher, van
Rossum, showed that haloperidol, an antipsychotic developed by Janssen in 1958, reduced
dopamine activity by blocking the dopamine receptor and tentatively suggested that this
finding may have implications for the etiology of schizophrenia (Van Rossum, 1966).
Although the dopamine hypothesis was not clearly articulated until the 1970s it appeared
to be widely known before this time (Moncrieff, 2009). Its origins lay in the relatively spe-
cific effects—in pharmacological terms—of haloperidol on dopamine receptors, and effects
that were not as clear with the broader acting drugs like chlorpromazine and reserpine.
By inferring a theory of the pathology of schizophrenia from the action of the drugs
used to treat it, the dopamine hypothesis assumes that the drugs act in a disease-centered
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way. References to the theory in textbooks and advertisements, however, indicate it was
regarded as supporting the disease-centered theory of drug action. Regardless of whether
or not there was any empirical evidence for the idea, the speculation that the dopamine
blocking effects of antipsychotics indicated the origins of the condition of schizophrenia
strengthened the emerging idea that the drugs acted by reversing an underlying biochemical
abnormality.
Discussion
The psychiatrists who started using the new drugs in the 1950s welcomed them enthusias-
tically, regardless of whether they understood them according to the drug-centered model,
as novel psychotropic substances with a uniquely useful profile of action, or whether they
believed them to be a new, and possibly the first, disease-specific treatment for serious men-
tal illness (Moncrieff, 1999a). Delay and Deniker were as convinced of the importance of
the discovery of the new drugs as anyone else in psychiatry (Delay & Deniker, 1955).
Interest in the new drugs continued but, in the space of a few years, the way they
were understood changed fundamentally. From being viewed as drugs that induced a
characteristic and useful state of neurological suppression, they were transformed into a
disease-specific treatment for schizophrenia. The altered mental and physical state induced
by the drugs came to be seen as irrelevant to their therapeutic action. The more subtle
emotional and behavioral effects disappeared from the literature altogether. The charac-
teristic “extrapyramidal” motor effects, although recognized as a marker for drugs with
antipsychotic action, came to be seen as quite distinct from the desired effects and were
relegated to the status of “side effects.” This transformation was not inspired by the results
of empirical research, or even informed debate, however. The idea that the drugs were dis-
ease specific simply appeared to replace the older view, which subsequently ceased to be
even acknowledged, suggesting that the process of transformation was driven by factors
other than the scientific merits of the disease-centered view.
The drivers of this metamorphosis included the psychiatric profession, which, since
it identified itself as a profession in the nineteenth century had felt the continued need to
justify the role of medicine in caring for people deemed at the time to be “insane” (Rogers
& Pilgrim, 2001; Scull, 1993). This insecurity continued into the twentieth century and it
was in this context that physical treatments like ECT and lobotomy were welcomed into
psychiatry (Moncrieff & Crawford, 2001). The new drugs helped bring psychiatry further
into line with existing medical practice, and contemporaries were delighted that the drugs
made “the mental hospital a medical institution in the minds of the public” (Overholser,
1956). In 1975, Jonathan Cole commented that “for the first time, public mental institutions
could be regarded as true treatment centres, rather than as primarily custodial facilities”
(Davis & Cole, 1975, p. 442). Deniker, too, described approvingly how the new drugs had
strengthened the medical and scientific approach in psychiatry (Deniker, 1970).
The drug-centered view of how psychiatric drugs might work was not, however, a
model that could be easily married with the increasingly specific nature of other medical
treatments. Moreover, the suggestion that the drugs acted by neurological suppression or
restriction provided ammunition for critics like Thomas Szasz, who portrayed the drugs as
chemical strait jackets that were used in the project of psychiatric social control (Szasz,
1957). Szasz published Myth of Mental Illness in 1960, and psychiatry came under attack
from various sources through the 1960s and 1970s as the antipsychiatry movement pro-
gressed. Budgetary constraints and the introduction of managed care in the United States
also increased competition from nonmedical therapists (Wilson, 1993). The profession
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reacted by attempting to strengthen its medical and scientific credentials, and the idea of
the specificity of drug treatment became a central part of that endeavor (Moncrieff, 2008b).
The specificity of drug treatment was cited in response to the Rosenhan experiment, for
example (Spitzer, 1976), in which normal volunteers obtained admission to mental hospi-
tals and were diagnosed with schizophrenia, apparently calling into question the validity
of psychiatric diagnosis (Rosenhan, 1973). More importantly, however, large areas of bio-
chemical and pharmaceutical research were instigated that in itself, regardless of its results,
helped portray psychiatry as a credible and thriving scientific enterprise.
Other factors are likely to have influenced the rise of the disease-centered view of
drug treatment, however. The rise of a recreational drug culture has been suggested to
have increased the inclination to distinguish between “drugs” and medicines and to play
down the ability of medical drugs to produce altered mental states (DeGrandpre, 2006).
Regulatory changes passed during the 1960s are also likely to have been influential, par-
ticularly the Kefauver-Harris amendment to the Food and Drug Act in the United States
that passed in response to the thalidomide tragedy (Anderson, 2005). This amendment
mandated companies to provide evidence of efficacy as well as safety in order to obtain
a license for their products. The need to specify each situation in which a drug was thought
to work reduced the ability of companies to market drugs across a range of indications and
encouraged association between particular drugs and particular disorders.
Regulatory restrictions, as well as professional directions, are likely to have influenced
the changing portrayal of antipsychotic drugs in advertising. Up to the 1970s, advertise-
ments for many substances reflected the marketing advantages of a drug-centered model
in aiming at a broad range of psychiatric situations. By the end of the 1970s, however,
the industry appeared to have come into line with the professional view, and the drugs
were mostly portrayed as specific treatments for schizophrenia with references to their
drug-induced effects expunged.
In the present day, by contrast, it is the pharmaceutical industry that most explicitly pro-
motes the disease-centered view of antipsychotics and other psychiatric drugs with material
on company Web sites frequently referring to the idea that drugs reverse chemical imbal-
ances (Moncrieff, 2006). The promotion of this view appears to contradict the growing
tendency for antipsychotics to be used in a variety of disorders including depression and
in situations like insomnia and agitation in the elderly where drug-induced sedation is the
intended effect (Verdoux, Tournier, & Begaud, 2010). These apparently conflicting tenden-
cies may be complementary, however. The text on the Eli Lilly Web site cited earlier with
its emphasis on how drugs “balance chemicals found naturally in the brain” illustrates how
the disease-centered notion that drug treatment is restorative can present a benign view of
drug treatment (Eli Lilly, 2011). This message provides a useful counterbalance to unfold-
ing evidence about the adverse effects of these drugs (Ray et al., 2009; Newcomer & Haupt,
2006), which is necessary for the successful promotion of these drugs to people with less
severe problems.
The fact that the term “antipsychotic” has become the most popular way of describing
the group of drugs I have described indicates the current hegemony of the disease-centered
view of their action. With rapidly increasing rates of prescription of antipsychotics, in gen-
eral, and newer “atypical” antipsychotics, in particular (Ilyas & Moncrieff, 2012), it is
timely to remind ourselves that these drugs were not always viewed in this way. The drug-
centered view of antipsychotics highlighted the artificial state induced by the drugs and
the unwanted knowledge, and potentially dangerous aspects of this state, which has been
occluded by the view that they work by reversing disease processes. The fact that our cur-
rent view of drug action was not established on scientific merit but represents the interplay
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of professional, commercial, and political concerns suggests the need to reevaluate the basis
on which these drugs are used.
References
American Psychiatric Association (1996): Schizophrenia. Washington, DC, American Psychiatric
Association.
Anderson S (2005): Drug regulation and the welfare state: Government, the pharmaceutical indus-
try and the health professions in Great Britain 1940—1980. In: Berridge V, Loughlin K, eds.,
Medicine, the Market and the Mass Media. London, Routledge, pp. 192–217.
Anton-Stephens D (1954): Preliminary observations on the psychiatric uses of chlorpromazine
(Largactil). Journal of Mental Science 100: 543–557.
Braslow J (1997): Mental Ills and Bodily Cures. Berkeley, CA, University of California Press.
Carlsson A, Lindqvist M (1963): Effect of chlorpromazine or haloperidol on formation of 3methoxy-
tyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica (Copenh)
20: 140–144.
Comite Lyonnais de Recherches Therapeutiques en Psychiatrie (2000): The birth of psy-
chopharmacotherapy: Explorations in a new world—1952—1968. In: Healy D, ed., The
Psychopharmacologists, Vol. III. London, Arnold, pp. 1–53.
Crane GE (1956): Further studies on iproniazid phosphate. Journal of Nervous and Mental Disease
124: 322–331.
Davis JM (1980): Antipsychotic drugs. In: Kaplan HI, Freedman AM, Sadock BJ, eds.,
Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 3rd edition, pp.
2257–2289.
Davis JM, Cole J (1975): Antipsychotic drugs. In: Freedman DX, Dyrud, JE, eds., American
Handbook of Psychiatry, Vol. 5. New York, Basic Books, 2nd edition, pp. 441–475.
DeGrandpre, R (2006): The Cult of Pharmacology: How America Became the world’s Most Troubled
Drug Culture. Durham, NC, Duke University Press.
Delay J, Deniker P (1952): 38 cas de psychoses triates par la cure prolongee et continue de 4560 R.P.
Congrès des Médecins Aliénistes et Neurologistes de Langue Francaise 50: 503–513.
Delay J, Deniker P (1955): Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry.
International Record of Medicine and General Practice Clinics 168: 318–326.
Delay J, Deniker P (1956): Chlorpromazine and neuroleptic treatments in psychiatry. Journal of
Clinical and Experimental Psychopathology 17: 19–24.
Delay J, Deniker P, Green A, Mordret M (1957): Excito-motor syndrome provoked by neuroleptic
drugs. Presse Medicale 65: 1771–1774.
Delay J, Deniker P, Harl JM (1952): Therapeutic use in psychiatry of phenothiazine of central elective
action (4560 RP). Annales Medico-Psychologiques (Paris) 110: 112–117.
Denham J (1965): Clinical use of the phenothiazines. In: Marks J, Pare CMB, eds., The Scientific
Basis of Drug Therapy in Psychiatry: Proceedings of a Symposium Held at St. Bartholomew’s
Hospital, London. London, Pergamon Press, pp. 56–61.
Denham J, Carrick DJ (1960): Therapeutic importance of extrapyramidal phenomena evoked by a
new phenothiazine. American Journal of Psychiatry 116: 927–928.
Deniker P (1956): Psychophysiologic aspects of the new chemotherapeutic drugs in psychiatry: Some
practical features of neuroleptics in order to screen new drugs. Journal of Nervous and Mental
Disease 124: 371–376.
Deniker P (1960). Experimental neurological syndromes and the new drug therapies in psychiatry.
Comprehensive Psychiatry 1: 92–102.
Deniker P (1970): Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd F, Blackwell B,
eds., Discoveries in Biological Psychiatry. Philadelphia, J B Lippincott Company, pp. 155–164.
Deniker P (1989): From chlorpromazine to tardive dyskinesia (brief history of the neuroleptics).
Psychiatric Journal of the University of Ottawa 14: 253–259.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 05
:55
 28
 Ju
ly 
20
14
 
Magic Bullets for Mental Disorders 43
Droleptan advertisement (1980): Droleptan advertisement. British Journal of Psychiatry 136(April).
Eli Lilly (2011): How Zyprexa works. Retrieved from www.zyprexa.com/schizophrenia/pages/
howzyprexaworks.aspx
Elkes J, Elkes C (1954): Effects of chlorpormazine on the behaviour of chronically overactive
psychotic patients. British Medical Journal II: 560–565.
Fentazin advertisement (1975): Fentazin advertisement. British Journal of Psychiatry 126(February).
Flugel F (1959): Clinical and investigative aspects. In: Kline NS, ed., Psychopharmacology Frontiers:
Second International Congress of Psychiatry Psychopharmacology Symposium. London, J&A
Churchill Ltd., pp. 45–47.
Freyhan FA (1959): Clinical and investigative aspects. In: Kline NS, ed., Psychopharmacology
Frontiers: Second International Congress of Psychiatry Psychopharmacology Symposium.
London, J&A Churchill Ltd., pp. 7–14.
Gelman S (1999): Medicating Schizophrenia: A History. New Brunswick, NJ, Rutgers University
Press.
Haase HJ (1954): Occurrence and interpretation of psychomotor parkinsonism in megaphen or
largactil prolonged therapy. Nervenarzt 25: 486–492.
Haase HJ (1956): Definition and mode of action of the psychomotor Parkinson syndrome ther-
apeutically induced by serpasil and largactil. Monatsschrift Psychiatrie fur Neurologie 131:
201–214.
Haase H-J, Janssen PAJ (1965): The Action of Neuroleptic Drugs. Chicago, Yearbook Medical
Publishers.
Healy D (1996): The Psychopharmacologists: Interviews by David Healy (Vol. I). London, Chapman
and Hall.
Healy D (1999): The Psychopharmacologists (Vol. II). London, Arnold.
Healy D (2000): The Psychopharmacologists (Vol. III). London, Arnold.
Healy D (2002): The Creation of Psychopharmacology. Cambridge, MA, Harvard University
Press.
Henderson D, Gillespie RD (1962): Henderson and Gillespie’s Textbook of Psychiatry. Oxford,
Oxford University Press, 9th edition.
Himwich HE (1955): Prospects in psychopharmacology. Journal of Nervous and Mental Disease
122: 413–423.
Hoch P (1959): Drug therapy. In: Arieti S, ed., American Handbook of Psychiatry (Vol. II). New
York, Basic Books, 1st edition, pp. 1541–1551.
Hollister LE (1957): Complications from the use of tranquilizing drugs. New England Journal of
Medicine 257: 170–177.
Ilyas S, Moncrieff J (2012): Trends in prescriptions and costs of drugs for mental disorders in
England, 1998 to 2010. British Journal of Psychiatry 77: 86–92.
Karn WN, Jr., Kasper S (1959): Pharmacologically induced Parkinson-like signs as index of the
therapeutic potential. Diseases of the Nervous System 20: 119–122.
Kinross-Wright V (1956): Clinical application of chlorpormazine. In: Kline NS, ed.,
Psychopharmacology: A Symposium Organised by the Section on medical Sciences for the
American Association of the Advancement of Science and the American Psychiatric Association.
Washington DC, American Association for the Advancement of Science, pp. 31–38.
Kline NS (1956): Chemotherapy in psychiatry: Recent advances. Seminars International 5: 7–10.
Kline NS (1959): Psychopharmaceuticals: Effects and side effects. Bulletin of the World Health
Organisation 21: 397–410.
Kline NS (1969): Nomenclature vs. nature. International Journal of Psychiatry 7: 292–293.
Laborit H, Huguenard P (1951): Artificial hibernation by pharmacodynamical and physical means.
Presse Medicale 59: 1329.
Laborit H, Huguenard P, Alluaume R (1952): A new vegetative stabilizer; 4560 R.P.. Presse Medicale
60: 206–208.
Largactil advertisement (1965): Largactil advertisement. British Journal of Psychiatry 111
(January): x.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 05
:55
 28
 Ju
ly 
20
14
 
44 Joanna Moncrieff
Lehmann H (1959). Concepts, rationale and research. In: Kline NS, ed., Psychopharmacology
Frontiers: Second International Congress of psychiatry Psychopharmacology Symposium.
London, J & A Churchill Ltd., pp. 21–30.
Lehmann HE (1993): Before they called it psychopharmacology. Neuropsychopharmacology 8:
291–303.
Lehmann HE, Hanrahan GE (1954): Chlorpromazine: New inhibiting agent for psychomotor excite-
ment and manic states. American Medical Association Archives of Neurology and Psychiatry 71:
227–237.
Maas JW, Garver DL (1975): Linkage of basic neuropharmacology and clinical
psychopharmacology. In: Hamburg DA, Brodie HKH, eds., American Handbook of Psychiatry
(Vol. 6). New York, Basic Books, 2nd edition, pp. 427–459.
Malitz S, Hoch P (1966): Drug therapy: Neuroleptics and tranquilizers. In: Arieti S, ed., American
Handbook of Psychiatry (Vol. III). New York, Basic Books, 2nd edition, pp. 458–476.
Mapp Y, Nodine JH (1962): Psychopharmacology: II. Tranquilizers and antipsychotic drugs.
Psychosomatics 3: 458–463.
Mayer-Gross W, Slater E, Roth M (1960): Clinical Psychiatry. London, Cassell & Co., 2nd edition.
Mayer-Gross W, Slater E, Roth M (1969): Clinical Psychiatry. London, Bailliere Tindall,
3rd edition.
Melleril advertisement (1960): Melleril advertisement. Journal of Mental Science 106(April): iii–vii.
Melleril advertisement (1965): Melleril advertisement. British Journal of Psychiatry 111(February):
i–vi.
Melleril advertisement (1970): Melleril advertisement. British Journal of Psychiatry 117(September):
xii–xiii.
Meltzer HY, Babo WV (2009): Antipsychotic and anticholinergic drugs. In: Gelder MG, Andreasen
NC, Lopez-Ibor JJ, Jr., Geddes JR, eds., New Oxford Textbook of Psychiatry. Oxford, Oxford
University Press, pp. 1208–1231.
Meyers FH (1956): Pharmacology of chlorpormazine, reserpine and related drugs. In: Kline
NS, ed., Psychopharmacology: A symposium held by the Section on Medical Sciences of the
American Association for the Advancement of Science and the American Psychiatric Association.
Washington DC, American Association for the Advancement of Science, pp. 131–140.
Moncrieff J (1999): An investigation into the precedents of modern drug treatment in psychiatry.
History of Psychiatry 10: 475–490.
Moncrieff J (2006): Psychiatric drug promotion and the politics of neo-liberalism. British Journal of
Psychiatry 188: 301–302.
Moncrieff J (2008a): The creation of the concept of the antidepressant: An historical analysis. Social
Science and Medicine 66: 2346–2355.
Moncrieff J (2008b): The Myth of the Chemical Cure: A Critique of psychiatric Drug Treatment.
Basingstoke, Hampshire, UK, Palgrave Macmillan.
Moncrieff J (2009): A critique of the dopamine hypothesis of schizophrenia and psychosis. Harvard
Review of Psychiatry 17: 214–225.
Moncrieff J, Cohen D (2005): Rethinking models of psychotropic drug action. Psychotherapy and
Psychosomatics 74: 145–153.
Moncrieff J, Crawford MJ (2001): British psychiatry in the 20th century—Observations from a
psychiatric journal. Social Science and Medicine 53: 349–356.
National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group
(1964): Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry 10:
246–258.
Neulactil advertisement (1970): Neulactil advertisement. British Journal of Psychiatry
116(February): iii.
Newcomer JW, Haupt DW (2006): The metabolic effects of antipsychotic medications. Canadian
Journal of Psychiatry 51: 480–491.
Overholser W: (1956): Has chlorpromazine inaugurated a new era in mental hospitals? Journal of
Clinical and Experimental Psychopathology 17: 197–201.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 05
:55
 28
 Ju
ly 
20
14
 
Magic Bullets for Mental Disorders 45
Pellegrino ED (1979): The socio-cultural impact of twentieth century therapeutics. In: Vogel MJ,
Rosenberg CE, eds., The Therapeutic Revolution. Philadelphia, PA, University of Pennsylvania
Press, pp. 245–266.
Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009): Atypical antipsychotic drugs and the risk
of sudden cardiac death. New England Journal of Medicine 360: 225–235.
Redeptin advertisement (1975): Redeptin advertisement. British Journal of Psychiatry 126(June).
Reserpine advertisement (1956): Reserpine advertisement. Journal of Mental Science 102
(January): vi.
Roberts MHT (1973): Pharmacology of drugs of importance in psychiatry. In: Forrest A, ed.,
Companion to Psychiatric Studies (Vol. 1). Edinburgh, Churchill Livingstone, 1st edition, pp.
348–385.
Rogers A, Pilgrim D (2001): Mental Health Policy in Britain. Basingstoke, Hampshire, Palgrave
Macmillan, 2nd edition.
Rosenberg CE (1986): Disease and social order in America: Perceptions and expectations. Milbank
Quarterly 64: 34–55.
Rosenhan DL (1973): On being sane in insane places. Science 179: 250–258.
Royal College of Psychiatrists (2007): Antidepressants. London, Royal College of Psychiatrists.
Sainz AA (1956): Considerations on the cerebral action of Reserpine. In: Kline NS, ed.,
Psychopharmacology: A Symposium Held by the Section on medical Sciences of the American
Association for the Advancement of Science and the American Psychiatric Association.
Washington DC, American Association for the Advancement of Science, pp. 59–63.
Sarwer-Foner GJ (1960): The role of neuroleptic medication in psychotherapeutic interaction.
Comprehensive Psychiatry 1: 291–300.
Scull A (1993): The Most Solitary of Afflictions. New Haven, Yale University Press.
Serenace advertisement (1965): Serenace advertisement. British Journal of Psychiatry 111(January):
xiii.
Serenace advertisement (1970): Serenace advertisement. British Journal of Psychiatry
116(February): xv.
Serenace advertisement (1975): Serenace advertisement. British Journal of Psychiatry 126(March):
vi–vii.
Shorter E (1997): A history of Psychiatry: From the Era of the Asylum to the Age of Prozac. New
York, John Wiley & Sons.
Sigwald J & Bouttier D (1953): Le chlorhydrate de cloro-3(dimethylamine-3-propyl)-10-
phenothiazine en practique neuro-psychiatrique courante. Annals Medicale 54: 150–184.
Smith Kline & French Laboratories (1955): Chlorpormazine and Mental Health: Proceedings
Held Under the Auspices of Smith Kline & French Laboratories. Philadelphia, Lea &
Febiger.
Smythies JR (1973): Drug treatment of schizophrenia. In: Forrest A, ed., Companion to Psychiatric
Studies (Vol. 2). Edinburgh, Churchill Livingstone, pp. 250–288.
Snyder SH (1980): Basic science of psychopharmacology. In: Kaplan HI, Freedman AM, Sadock
BJ, eds., Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 3rd edition, pp.
154–165.
Spitzer RL (1976): More on pseudoscience in science and the case for psychiatric diagnosis. A cri-
tique of D. L. Rosenhan’s “On Being Sane in Insane Places” and “The Contestual Nature of
Psychiatric Diagnosis.” Archives of General Psychiatry 33: 459–470.
Steck H (1954): Le syndrome extra-pyramidal et di-encephalique au cours des traitments au Largactil
at au Serpasil. Annales Medico-Psychologiques 112: 737–743.
Stelazine advertisement (1965a). Stelazine advertisement. British Journal of Psychiatry
111(February): ii.
Stelazine advertisement (1965b). Stelazine advertisement. British Journal of Psychiatry
111(September): xiv.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 05
:55
 28
 Ju
ly 
20
14
 
46 Joanna Moncrieff
Sussman N (2009): General principles of psychopharmacology. In: Sadock BJ, Sadock VA, Ruiz P,
eds., Comprehensive Textbook of Psychiatry. Philadelphia, Wolters Kluwer/Lippincott Williams
& Wilkins, 9th edition, pp. 2965–2988.
Swazey J (1974): Chlorpromazine in Psychiatry. Cambridge, MA, Massachusetts Institute of
Technology.
Szasz T (1957): Some observations on the use of tranquilizing drugs. AMA Archives of Neurology
and Psychiatry 77: 86–92.
Triperidol advertisement (1970): Triperidol advertisement. British Journal of Psychiatry
116(February): i.
Van Rossum JM (1966): The significance of dopamine receptor blockade for the action of neuroleptic
drugs. In: Brill H, ed., Neuro-psycho-pharmacology. Amsterdam, Excerpta Medica Foundation,
pp. 321–329.
Verdoux H, Tournier M, Begaud B (2010): Antipsychotic prescribing trends: A review of pharmaco-
epidemiological studies. Acta Psychiatrica Scandinavia 121: 4–10.
Whitaker R (2002): Mad in America. Cambridge, MA, Perseus Publishing.
Wilson M (1993): DSM-III and the transformation of American psychiatry: A history. American
Journal of Psychiatry 150: 399–410.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 C
oll
eg
e L
on
do
n]
 at
 05
:55
 28
 Ju
ly 
20
14
 
